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Abstract
Background: Hepatic mitochondrial dysfunction plays an important role in the pathogenesis of non-alcoholic
fatty liver disease (NAFLD). Methyl donor supplementation has been shown to alleviate NAFLD, connecting the
condition to the one-carbon metabolism. Thus, the objective was to investigate regulation of homocysteine (Hcy)
and metabolites along the choline oxidation pathway during induction of hepatic steatosis by the fatty acid
analogue tetradecylthiopropionic acid (TTP), an inhibitor of mitochondrial fatty acid oxidation.
Methods: Mice were fed a control diet, or diets containing 0.3 %, 0.6 %, or 0.9 % (w/w) TTP for 14 days. Blood
and liver samples were collected, enzyme activities and gene expression were analyzed in liver, lipid and fatty acid
composition in liver and plasma, one-carbon metabolites, B-vitamin status, carnitine and acylcarnitines were
analyzed in plasma.
Results: Liver mitochondrial fatty acid oxidation decreased by 40 % and steatosis was induced in a dose
dependent manner; total lipids increased 1.6-fold in animals treated with 0.3 % TTP, 2-fold with 0.6 % TTP and 2.1
fold with 0.9 % TTP compared to control. The higher hepatic concentration of fatty acids was associated with
shortening of carbon-length. Furthermore, the inhibited fatty acid oxidation led to a 30-fold decrease in plasma carnitine
and 9.3-fold decrease in acetylcarnitine at the highest dose of TTP, whereas an accumulation of palmitoylcarnitine
resulted. Compared to the control diet, TTP administration was associated with elevated plasma total Hcy (control:
7.2 ± 0.3 umol/L, 0.9 % TTP: 30.5 ± 5.9 umol/L) and 1.4-1.6 fold increase in the one-carbon metabolites betaine,
dimethylglycine, sarcosine and glycine, accompanied by changes in gene expression of the different B-vitamin
dependent pathways of Hcy and choline metabolism. A positive correlation between total Hcy and hepatic
triacylglycerol resulted.
Conclusions: The TTP-induced inhibition of mitochondrial fatty acid oxidation was not associated with increased
hepatic oxidative stress or inflammation. Our data suggest a link between mitochondrial dysfunction and the
methylation processes within the one-carbon metabolism in mice.
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Background
The liver is important in regulating lipid homeostasis and
metabolism [1] and under normolipidemic conditions all
fat to the liver is either oxidized or secreted as very low-
density lipoprotein-triacylglycerols (VLDL-TAGs) and fi-
nally stored in white adipose tissue. However, the preva-
lence of excessive accumulation of hepatic fat unrelated to
alcohol consumption (hepatic steatosis or non-alcoholic
fatty liver disease (NAFLD)) has increased in adults of in-
dustrialized countries [2]. Moreover, its development often
parallels that of obesity-associated diseases like insulin re-
sistance, metabolic syndrome, dyslipidemia, and type 2
diabetes mellitus, and there is a strong association be-
tween NAFLD and risk of CVD [3].
Over time, an excess uptake of lipids to the liver will
require an adaptive increase in mitochondrial oxidative
capacity. An increased exposure to oxidative stress and
inflammation may lead to dysregulated mitochondrial
function, which is central for the intrahepatic accumula-
tion of lipids [4, 5]. Reduced fatty acid oxidation, as well
as increased adipose tissue lipolysis and liver lipid uptake
can cause excessive accumulation of hepatic TAG. Per-
ipheral insulin resistance will lead to hyperglycemia and
increased hepatic lipogenesis, while hyperinsulinemia
will inhibit lipoprotein synthesis and secretion [6]. The
antioxidant capacity of the diet could potentially play a
vital role in the development of NAFLD and the preven-
tion of CVD-risk [7], in part by maintaining mitochon-
drial function.
Tetradecylthiopropionic acid (TTP) is a synthetic sat-
urated fatty acid (SFA) with a sulphur atom in the 4-
position from the carboxylic end. This implies that the
fatty acid derivative can undergo only one cycle of
mitochondrial β-oxidation [8]. The weak peroxisomal
proliferator fatty acid TTP will then induce fatty liver
by the accumulation of alkylthioacryloyl-CoA, which is
believed to inhibit carnitine palmitoyl transferase 2
(CPT II) [8–10]. In addition, an accelerated TAG bio-
synthesis due to stimulation of the enzyme phosphati-
date phosphohydrolase has been proposed [11, 12].
We have recently shown that elevated plasma choline
[13] and dimethylglycine (DMG) [14, 15] are associated
with an increased risk of acute myocardial infarction.
Plasma total homocysteine (tHcy) is a well-known risk
marker for CVD and hyperhomocysteinemia is associ-
ated with alterations in intracellular lipid metabolism
[16]. Moreover, during oxidative stress the one-carbon
cycle shifts from methylation pathways to the transsul-
furation pathway [17]. Previous knowledge regarding the
influence of TTP-induced fatty liver on the circulating
levels of metabolites along the choline oxidation path-
way is scarce. The choline oxidation pathway is a vital
part of Hcy metabolism and could potentially be affected
by mitochondrial dysfunction as it is located in the
mitochondrial compartment. Since a dietary deficiency in
methyl donors may lead to fatty liver [18], we aimed to in-
vestigate how tHcy and metabolites along the choline oxi-
dation pathway were regulated during TTP-induced fatty
liver (Fig. 1). The present study suggests that reduced
mitochondrial function and fatty liver is associated with
low carnitine and acetylcarnitine concentrations and ele-
vated plasma palmitoylcarnitine. Oxidative stress was,
however, not increased. In addition, TTP resulted in ele-
vated plasma tHcy through interfering with all three vita-
min B-dependent pathways of Hcy metabolism, including
transsulfuration.
Results
Effect on body and liver weights and feed intake
C57BL/6 mice were fed a control diet containing 7 % (w/w)
fat for two weeks, or the same diet supplemented with 0.3,
0.6 or 0.9 % TTP. Mice fed the TTP diets had a significantly
lower feed intake than mice fed the control diet, and this
was accompanied by a significantly lower body weight
(Table 1). The hepatic index (ratio liver weight to body
weight) was, however, unchanged. Alanine transaminase
(ALT) in plasma tended to increase, but these data were
not statistically significant.
Hepatic fatty liver
There was increased lipid droplet accumulation in hepa-
tocytes after TTP treatment, resulting in abnormalities
in liver morphology (Fig. 2). Moreover, the total liver
lipids increased 2-fold and 2.1-fold at dosages 0.6 and
0.9 % of TTP, respectively (Fig. 3a). This was due to an
increase in TAG (Fig. 3b) and cholesterol (Fig. 3c), while
hepatic phospholipid levels were not changed in TTP-
treated mice compared to controls (Fig. 3d). The higher
hepatic concentration of fatty acids (data not shown)
was mainly due to increased wt % of MUFAs, while
SFAs and n-6 PUFAs were significantly decreased and n-
3 PUFAs were unchanged. The decreased relative
amount of n-6 PUFAs was due to decreased wt % of
long chain fatty acids, reflecting a decreased content of
C20:4n-6 (arachidonic acid, AA), C20:2n-6, C20:3n-6
and C22:5n-6, while C18:2n-6 (linoleic acid, LA) was un-
changed (data not shown). It is worth noting that
C18:3n-3 (α-linolenic acid, ALA) and C18:4n-3 was sig-
nificantly increased at the lowest TTP dose, whereas
C20:5n-3 (eicosapentaenoic acid, EPA), C22:5n-3 (doco-
sapentaenoic acid, DPA), and C22:6n-3 (docosahexae-
noic acid, DHA) was unchanged after TTP treatment.
As a result, the ratio of n-3 to n-6 PUFAs was higher in
TTP-treated animals. The n-9 PUFAs were unchanged
by TTP administration (data not shown), but most of
the long-chain MUFAs (C20-C24), both of the n-7 and
n-9 family, decreased. Thus, the increase in total MUFAs
was due to the relative higher amount of C18:1n-9,
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C16:1n-7, and C16:1n-9 in TTP-treated mice (Table 2).
Moreover, it was of interest that the relative amount of
long-chain SFAs such as C18:0, C20:0, C22:0 and C24:0
was decreased, whereas the content of medium chain
SFAs as C12:0 and C14:0 was increased (Table 2). C16:0
was not changed by TTP treatment (data not shown).
Hepatic fatty acid oxidation and plasma carnitine
derivatives
The hepatic mitochondrial β-oxidation, measured as acid
soluble products from palmitoyl-CoA (Fig. 4a) was de-
creased in fresh liver homogenates from TTP-treated
mice. The sensitivity to malonyl-CoA-inhibition was re-
duced in TTP-treated mice compared to controls (Fig. 4b).
Unexpectedly, the activities of mitochondrial CPT I and II
were increased by TTP treatment (Fig. 4c, d), as was the
HMG-CoA synthase activity (Fig. 4e). Thus, enzymes
involved in both import of fatty acids to the mitochondria
and ketone body production was increased by TTP. More-
over, the hepatic citrate synthase activity, often used as a
matrix enzyme marker for intact mitochondria, was in-
creased in mice treated with TTP (Fig. 4f). Furthermore,
hepatic fatty acyl-CoA oxidase 1 (ACOX1) activity in-
creased in a dose-dependent manner suggesting an induc-
tion of the peroxisomal β-oxidation system (Fig. 4g). The
acyl-CoA synthetase (ACSL) activity was also increased by
TTP administration (Fig. 4h). The activities of fatty acid
synthase (FAS), an enzyme involved in lipogenesis, and
glycerol-3-phosphate acyltransferase (GPAT), an enzyme
involved in TAG biosynthesis, were unchanged (data not
shown).
Gene expression of fatty acid binding protein (Fabp1),
peroxisome proliferator-activated receptor gamma (Pparg),
PPAR gamma coactivator 1 alpha (Ppargc1a), CD36 and
Fig. 1 Metabolites of the homocysteine remethylation and sulfoxation, transsulfuration, and choline oxidation pathways. Names of enzymes are
beside the arrows. Vitamins involved in the enzymatic reactions are shown in green circles. Abbreviations: BADH, betaine aldehyde dehydrogenase;
BHMT, betaine-homocysteine methyltransferase; CBS, cystathionine beta-synthase; CHDH, choline dehydrogenase; CTH, cystathionine gamma-lyase;
DMG, dimethylglycine; DMGDH, dimethylglycine dehydrogenase; GNMT, glycine N-methyltransferase; Hcy, homocysteine; MAT, methionine
adenosyltransferase; Met, methionine; MetSO, methionine sulfoxide; 5-mTHF, 5-methyltetrahydrofolate; MTs, methyltransferases; MTR,
methionine synthase; MSR (encoded by the gene Mtrr), methionine synthase reductase; PC, phosphatidylcholine; PE, phosphatidyletanolamine;
PEMT, phosphatidyl-ethanolamine methyltransferase; SAH, s-adenosylhomocysteine; SAM, s-adenosylmethionine; SARDH, sarcosine dehydrogenase;
SHMT1, serine hydroxymethyltransferase 1; SHMT2, serine hydroxymethyltransferase 2; THF, tetrahydrofolate; TML, trimethyllysine
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hepatic hormone sensitive lipase (Lipe) were all in-
creased after TTP treatment (Table 3). The mRNA
levels of hepatic lipase (Lipc), PPAR alpha (Ppara), ATP
citrate lyase, acylcarnitine translocase and ApoB
remained constant (Table 3).
L-carnitine is essential for mitochondrial oxidation of
long-chain fatty acids, and the plasma concentrations of
L-carnitine and its precursor γ-butyrobetaine were re-
duced in mice treated with TTP (Fig. 5a, b). The highest
dose of TTP gave the most prominent effect on L-
carnitine, reducing its level 30-fold compared to control.
Among plasma acylcarnitines, the long-chain palmitoyl-
carnitine was increased (Fig. 5c), and the medium-chain
octanoylcarnitine was reduced by 0.9 % TTP (Fig. 5d).
Table 1 Body weight, organ weight, feed intake, and plasma lipids in control and TTP-treated micea
Diet groups
Control 0.3 % TTP 0.6 % TTP 0.9 % TTP
Body weightb (g) 28.7 ± 1.1 23.8 ± 1.3*** 22.5 ± 0.8*** 22.4 ± 1.3***
Feed intakec (g) 4.2 ± 0.3 3.3 ± 0.7* 3.1 ± 0.9** 3.2 ± 0.4*
Hepatic indexd (%) 4.6 ± 0.7 4.5 ± 0.6 5.1 ± 0.7 5.0 ± 0.8
Plasma ALT (u/L) 29.7 ± 2.6 38.9 ± 25.8 31.8 ± 8.9 32.7 ± 6.9
Plasma TAG (mmol/L) 0.63 ± 0.11 0.60 ± 0.15 0.65 ± 0.17 0.51 ± 0.15
Plasma chol (mmol/L) 2.67 ± 0.41 2.62 ± 0.41 2.74 ± 0.23 3.08 ± 0.28
Plasma PL (mmol/L) 2.75 ± 0.35 2.62 ± 0.34 2.68 ± 0.25 2.75 ± 0.27
Plasma NEFA (mmol/L) 0.16 ± 0.06 0.37 ± 0.13 0.39 ± 0.30 0.50 ± 0.20**
Plasma glucose (mmol/L) 14.8 ± 2.1 12.1 ± 1.3* 11.0 ± 2.1*** 11.2 ± 1.0**
Abbreviations: ALT alanine aminotransferase; NEFA non-esterified fatty acids; TTP tetradecylthiopropionic acid; TAG triacylglycerol; PL phospholipids;
Chol, cholesterol
aValues are means with standard deviation (n = 7–8), and values statistically different from control were determined by one-way ANOVA with Dunnett’s post hoc
test (*P < 0.05, **P < 0.01, ***P < 0.001)
bBody weight after two weeks of treatment
cAverage feed intake per mouse per day calculated from measurements every 3 days throughout the experiment (n = 3)
dHepatic index was calculated as percentage of liver weight to body weight
Fig. 2 Lipid droplet morphology in frozen liver tissue sections from tetradecylthiopropionic acid (TTP) treated mice. Representative images of
Oil-red-O stained liver sections from male C57BL/6 mice fed a control low-fat diet, or low-fat diets supplemented with 0.3 % (w/w), 0.6 % or 0.9 %
TTP for 2 weeks (n = 3)
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The short-chain acylcarnitines propionyl-, (iso)valeryl-,
and acetylcarnitine were decreased in all TTP groups
(Fig. 5e-g), and a 9.3-fold reduction in acetylcarnitine
was observed in the 0.9 % TTP group compared to
control.
Plasma lipids and fatty acid composition
The plasma concentrations of TAG, cholesterol and
phospholipids were not changed by TTP treatment
(Table 1). Interestingly, the plasma level of NEFA in-
creased in a dose-dependent manner with TTP. There
were no changes in plasma wt % of SFAs, MUFAs
and n-6 PUFAs in TTP-treated mice, and only a
small increase in n-3 PUFAs in the 3 % TTP group
(Table 4). Between-group differences in plasma fatty
acids were less striking compared to hepatic fatty
acids (Table 2), with the exception of a lower level of
plasma 22:5n-6 in TTP animals. Altogether, this re-
sulted in an increased ratio of n-3 to n-6 PUFAs
(Table 4).
Antioxidant status and inflammation
During oxidative stress, fatty acids shorten in chain
length and decrease in unsaturation [17]. The plasma
total antioxidant capacity (Fig. 6a) significantly increased
after TTP administration. The fatty acid inflammatory
index increased in plasma (Fig. 6b) and liver (Fig. 6c),
and this was accompanied by significantly decreased
hepatic gene expression of IL-1β and TNFα after TTP
treatment (Table 3). The double bond index (DBI) was
unchanged in plasma (Fig. 6d), but reduced in liver
(Fig. 6e), and the hepatic mRNA levels of cytosolic
superoxide dismutase 1 (Sod1) and mitochondrial Sod2
were increased and remained constant, respectively
(Table 3).
Plasma metabolites in methylation pathways
No changes in the plasma concentrations of choline
were observed in mice fed TTP compared to controls
(data not shown). The plasma concentration of sarcosine
(Fig. 7a) was increased 1.6-fold in the 0.6 % TTP-treated























































































































Fig. 3 Hepatic lipid profile with increasing dose of tetradecylthiopropionic acid (TTP). Male C57BL/6 mice were fed a low-fat control diet (black),
or low-fat diets supplemented with 0.3 % (grey) (w/w), 0.6 % (dark grey) or 0.9 % (light grey) TTP for 2 weeks. Levels of (a) total hepatic lipids
(combination of triacylglycerol (TAG), cholesterol, and phospholipids), (b) TAG, (c) cholesterol, and (d) phospholipids were as indicated. Mean
values with SD are presented (n = 7-8), and statistically significant difference from control was determined by one-way ANOVA with Dunnett’s
post hoc test (*P < 0.05, **P < 0.01, ***P < 0.001)
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and glycine tended to increase in a dose-dependent
manner [t-test control vs 0.9 % TTP was P = 0.047
(Fig. 7b), P = 0.049 (Fig. 7c), P = 0.007 (Fig. 7d)]. The
serine level was unchanged (Fig. 7e).
The plasma levels of methionine (Fig. 7f ) and me-
thionine sulfoxide (Fig. 7g) were unchanged by TTP,
whereas tHcy (Fig. 7h) increased in a dose-dependent
manner in TTP-fed mice (control: 7.2 ± 0.3 umol/L,
0.9 % TTP: 30.5 ± 5.9 umol/L). The transsulfuration
pathway was also affected by TTP treatment, as the
plasma content of cysteine was decreased compared to
control (Fig. 7j). The plasma cystathionine level was
unchanged (Fig. 7i). The plasma level of the L-carnitine
precursor trimethyllysine was not significantly changed
after TTP treatment (Fig. 7k). Interestingly, there was a
strong correlation between plasma tHcy and hepatic
TAG concentration (correlation coefficient, r = 0.798,
P = 0.003; Fig. 7l).
Plasma vitamin B status
Several enzymes involved in the choline oxidation, trans-
sulfuration and folate cycle depend on B vitamins as co-
factors (Fig. 1). The plasma concentrations of the B2
vitamers flavine mononucleotide and riboflavin were not
changed in mice fed the TTP diet (Fig. 8a, b). The
plasma concentration of the B3 vitamer nicotinamide
was increased (Fig. 8c), while N1-methylnicotinamide
was unchanged by the TTP-diet (data not shown). The
plasma concentration of pyridoxal 5′ phosphate, the ac-
tive form of vitamin B6, was unchanged in TTP-fed
mice compared to control (Fig. 8d). Plasma pyridoxal
tended to increase in a dose-dependent manner (t-test
Table 2 Comparison of hepatic fatty acid composition in control and TTP-treated mice
Diet groups
Fatty acida (wt %) Control 0.3 % TTP 0.6 % TTP 0.9 % TTP
Σ SFA 32.0 ± 2.8 31.1 ± 1.5 29.3 ± 1.8* 29.0 ± 1.7**
C12:0 0.01 ± 0.003 0.05 ± 0.02* 0.05 ± 0.02** 0.05 ± 0.02**
C14:0 0.31 ± 0.09 0.53 ± 0.14** 0.69 ± 0.19*** 0.71 ± 0.17***
C18:0 10.3 ± 2.4 8.5 ± 1.4 6.6 ± 2.1** 6.7 ± 1.0**
C20:0 0.23 ± 0.05 0.14 ± 0.05*** 0.07 ± 0.03*** 0.06 ± 0.01***
C22:0 0.29 ± 0.07 0.21 ± 0.06* 0.11 ± 0.07*** 0.10 ± 0.04***
C24:0 0.22 ± 0.06 0.13 ± 0.02** 0.10 ± 0.05*** 0.09 ± 0.04***
Σ MUFAs 27.0 ± 5.1 29.7 ± 3.7 39.6 ± 8.8** 41.5 ± 5.1***
C16:1n-7 3.0 ± 0.9 3.6 ± 0.3 4.7 ± 1.5* 4.9 ± 1.3*
C16:1n-9 0.38 ± 0.14 0.58 ± 0.06* 0.82 ± 0.21*** 0.93 ± 0.18***
C18:1n-9 19.5 ± 5.1 22.6 ± 2.2 29.9 ± 6.4*** 31.8 ± 4.1***
C20:1n-7 0.18 ± 0.07 0.09 ± 0.02** 0.09 ± 0.05** 0.06 ± 0.03***
C22:1n-7 0.05 ± 0.01 0.02 ± 0.01*** 0.01 ± 0.01*** 0.01 ± 0.01***
C24:1n-9 0.27 ± 0.06 0.19 ± 0.03* 0.16 ± 0.06*** 0.14 ± 0.04***
Σ n-6 PUFAs 30.6 ± 3.7 27.8 ± 1.5 21.9 ± 6.1*** 20.7 ± 3.0***
C20:2n-6 0.25 ± 0.07 0.20 ± 0.03 0.18 ± 0.05* 0.17 ± 0.03*
C20:3n-6 1.7 ± 0.2 1.2 ± 0.1*** 0.9 ± 0.4*** 1.0 ± 0.2***
C20:4n-6 13.4 ± 2.1 10.5 ± 1.5** 6.8 ± 2.6*** 6.8 ± 1.2***
C22:5n-6 0.42 ± 0.29 0.18 ± 0.04* 0.12 ± 0.04** 0.13 ± 0.03**
Σ n-3 PUFAs 10.0 ± 0.9 11.1 ± 1.4 8.9 ± 3.1 8.5 ± 1.6
C18:3n-3 0.26 ± 0.06 0.51 ± 0.12* 0.48 ± 0.24* 0.51 ± 0.20*
C18:4n-3 0.02 ± 0.01 0.06 ± 0.02 0.07 ± 0.05* 0.07 ± 0.05*
C20:5n-3 0.39 ± 0.09 0.46 ± 0.07 0.43 ± 0.20 0.40 ± 0.15
C22:5n-3 0.28 ± 0.06 0.44 ± 0.04* 0.40 ± 0.20 0.39 ± 0.16
C22:6n-3 8.9 ± 0.8 9.5 ± 1.5 7.4 ± 2.7 7.0 ± 1.2
Σ n-3 PUFA/Σ n-6 PUFAb 0.33 ± 0.02 0.40 ± 0.04** 0.40 ± 0.06** 0.41 ± 0.04**
Abbreviations: SFAs saturated fatty acids; MUFAs monounsaturated fatty acids; PUFAs polyunsaturated fatty acids; TTP tetradecylthiopropionic acid
aMeans with standard deviation are shown (n = 7–8), and results were analyzed by one-way ANOVA with Dunnett’s post hoc test (P* < 0.05, P** < 0.01, P*** < 0.001)
bn-3 PUFA/n-6 PUFA calculated
as: (18:4n-3 + 18:3n-3 + 20:3n-3 + 20:4n-3 + 21:5n-3 + 22:6n-3 + 22:5n-3)/(18:3n-6 + 18:2n-6 + 20:4n-6 + 20:3n-6 + 20:2n-6 + 22:5n-6 + 22:4n-6 + 22:2n-6)
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control vs 0.9 % TTP: P = 0.083; Fig. 8e), and plasma 4-
pyridoxic acid was unchanged (Fig. 8f). The biological
function of cobalamin is to serve as a cofactor for MS and
methylmalonyl-coenzyme A mutase where the final prod-
uct MMA is utilized as a clinical marker of cobalamin de-
ficiency. It was of interest that the plasma MMA level
tended to be lower during TTP-induced fatty liver (Fig. 8g;
significant with t-test control vs 0.9 % TTP: P = 0.025).
Hepatic gene expression
The regeneration of choline to phosphatidylcholine
through the Kennedy pathway is catalysed by choline kin-
ase. In TTP-treated mice the hepatic gene expression of
choline kinase alpha (Chka) was decreased, while choline
kinase beta (Chkb) was increased (Table 3). Furthermore,
phosphocholine cytidyltransferase alpha (Pcyt1a) was sig-
nificantly decreased. Along the choline oxidation pathway
the mRNA level of choline dehydrogenase (Chdh) was un-
changed. The gene expression of serine hydroxymethyl-
transferase 2 (Shmt2), dimethylglycine dehydrogenase
(Dmgdh), sarcosine dehydrogenase (Sardh), as well as
betaine-homocysteine methyltransferase (Bhmt), however,
was significantly decreased. The mRNA levels of glycine
N-methyltransferase (Gnmt), transforming glycine to
sarcosine, and serine hydroxymethyltransferase 1 (Shmt1),
transforming cytosolic serine to glycine, were unchanged
by TTP administration.
The hepatic gene expression of methionine synthase
(Mtr) and methionine synthase reductase (Mtrr),
involved in the folate cycle, was reduced by TTP. In the
transsulfuration pathway, there was a significant reduc-
tion in the gene expression of cystathionine beta-
synthase (Cbs) whereas the mRNA level of cystathionine
gamma-lyase (Cth) was unchanged. Finally, we also ob-
served a significant reduced expression of mitochondrial
methionine sulfoxide reductase B2 (Msrb2), whereas the
expression of methionine sulfoxide reductase A (Msra)
was unchanged.
Discussion
The present study demonstrates that inhibition of mito-
chondrial β-oxidation by TTP administration results in
hepatic steatosis, accompanied by changes in plasma L-
carnitine derivatives and hepatic fatty acid composition.
In addition, changes in the expression of genes regulat-
ing plasma levels of metabolites along the B-vitamin
dependent pathways of Hcy and choline metabolism,
and a 4.3-fold increase plasma tHcy level was observed.
Fatty liver and mitochondrial dysfunction was observed
despite increased antioxidant activity and anti-
inflammatory effects after 2 weeks of TTP treatment.
TTP and fatty liver
Hepatic accumulation of TAG, cholesterol, and total fatty
acids was observed in TTP-treated mice (Fig. 3, Table 2).
This was associated with increased plasma concentration
of NEFA and an increased gene expression of hepatic Lipe
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e f g h
Fig. 4 The effect of tetradecylthiopropionic acid (TTP) on hepatic lipid metabolism in mice. Male C57BL/6 mice were fed a low-fat control diet
(black), or low-fat diets supplemented with 0.3 % (grey) (w/w), 0.6 % (dark grey) or 0.9 % (light grey) TTP for 2 weeks. a β-oxidation as measured
by degradation of palmitoyl-CoA in fresh liver homogenates. b Inhibition of the β-oxidation reaction in the presence of malonyl-CoA. The activities of
(c) Carnitine palmitoyl transferase (CPT)-I, (d) CPT-II, (e) HMG-CoA synthase, (f) citrate synthetase, (g) fatty acyl-CoA oxidase (ACOX1), and (h) acyl-CoA
synthase were measured in frozen liver homogenates. Mean values with SD are presented (a–c: n = 5 – 7, d–i: n = 7–8), and statistically significant
difference from control was determined by one-way ANOVA with Dunnett’s post hoc test (*P < 0.05, **P < 0.01, ***P < 0.001)
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fatty acids to the liver was probably associated with TTP-
induced fatty liver. The flux or draining of fatty acids to
the liver was also supported by an increased enzyme activ-
ity of fatty acyl-CoA synthetase (Fig. 4h), in parallel with
upregulated gene expression of fatty acid binding protein
(Table 3). In accordance with previous findings in rats,
TTP was associated with inhibited mitochondrial fatty
acid oxidation and decreased sensitivity to malonyl-CoA
Table 3 Hepatic gene expression levelsa
Gene symbol Gene name Control diet 0.9 % TTP diet P-value
PPAR co-activators:
Pparg1a Peroxisome proliferator-activated receptor gamma, coactivator 1 alpha 1.00 ± 0.32 1.56 ± 0.33 0.021
Ppara Peroxisome proliferator-activated receptor alpha 1.00 ± 0.37 1.12 ± 0.23 0.468
Pparg Peroxisome proliferator-activated receptor gamma, coactivator 1 beta 1.00 ± 0.78 1.57 ± 0.31 0.040
Fatty acid mobilization, uptake, and secretion:
CD36 Peroxisome proliferator-activated receptor gamma, coactivator 1 beta 1.00 ± 0.64 3.24 ± 0.67 <0.001
Lipe Hormone sensitive lipase 1.00 ± 0.16 1.24 ± 0.24 0.036
Lipc Hepatic lipase 1.00 ± 0.14 0.93 ± 0.15 0.384
Fabp1 Fatty acid binding protein 1, liver 1.00 ± 0.35 1.38 ± 0.27 0.039
Acly ATP citrate lyase 1.00 ± 0.22 0.97 ± 1.02 0.187
Apob Apolipoprotein B 1.00 ± 0.16 0.94 ± 0.14 0.450
Slc25a20 acylcarnitine translocase 1.00 ± 0.25 1.31 ± 0.44 0.116
Antioxidant activity and inflammation:
Tnfa Tumor necrosis factor alpha 1.00 ± 0.44 0.51 ± 0.09 0.014
Il1b Interleukin 1, beta 1.00 ± 0.63 0.68 ± 0.32 0.054
Sod1 Superoxide dismutase 1, soluble 1.00 ± 0.11 1.27 ± 0.22 0.010
Sod2 Superoxide dismutase 2, mitochondrial 1.00 ± 0.12 1.08 ± 0.11 0.187
Phosphatidyl synthesis and metabolism:
Chka Choline kinase alpha 1.00 ± 0.35 0.35 ± 0.14 <0.001
Chkb Ethanolamine kinase/Choline kinase beta 1.00 ± 0.18 1.49 ± 0.29 0.001
Pcyt1a Phosphate cytidylyltransferase 1, choline, alpha 1.00 ± 0.19 0.80 ± 0.08 0.018
Choline oxidation pathway, mitochondria:
Chdh Choline dehydrogenase 1.00 ± 0.35 1.01 ± 0.15 0.941
Dmgdh Dimethylglycine dehydrogenase precursor 1.00 ± 0.28 0.65 ± 0.07 0.007
Sardh Sarcosine dehydrogenase 1.00 ± 0.31 0.69 ± 0.14 0.032
Shmt2 Serine hydroxymethyltransferase 2 (mit) 1.00 ± 0.24 0.59 ± 0.10 0.001
Choline oxidation pathway, cytosol:
Bhmt betaine-homocysteine S-methyltransferase 1.00 ± 0.76 0.15 ± 0.05 0.012
Gnmt Glycine N-methyltransferase 1.00 ± 0.14 0.90 ± 0.15 0.232
Amino acid metabolism and derivatives:
Mtr/Mr Methionine synthase (5-methyltetrahydrofolate-homocystein methyltransferase) 1.00 ± 0.22 0.70 ± 0.12 0.006
Mtrr/Msr Methionine synthase reductase (5-methyltetrahydrofolate-homocystein) 1.00 ± 0.50 0.68 ± 0.17 0.040
Msra Methionine sulfoxide reductase A 1.00 ± 0.50 0.88 ± 0.21 0.556
Msrb2 Methionine sulfoxide reductase B2 1.00 ± 0.10 0.75 ± 0.14 0.001
Shmt1 Serine hydroxyl-methyltransferse (soluble) 1.00 ± 0.57 0.66 ± 0.23 0.165
Transsulfuration:
Cbs Cystathionine-beta-synthase 1.00 ± 0.46 0.49 ± 0.18 0.017
Cth Cystathionase (cystathionine gamma lyase) 1.00 ± 0.51 0.63 ± 0.22 0.121
Abbreviations: TTP tetradecylthiopropionic acid
aExpression levels were normalized to 18 s expression and relative values to control are given as means ± standard deviation (n = 7–8). Results were analyzed by
unpaired t-test, and P –values < 0.05 were considered significant
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inhibition of CPT I (Fig. 4b) [12, 19]. Previously, a dose
of 150 and 300 mg TTP/day/kg body weight resulted in
hepatic lipid accumulation in rats [11]. A goal of the
current study was to determine the optimal dose of
TTP with regard to hepatic steatosis in mice, as mice
have a higher metabolic rate than rats. The effect of 0.3,
0.6 or 0.9 % (w/w) TTP in the diet was investigated.
Two weeks treatment with both 0.6 and 0.9 % TTP-
diets, calculated to a dose of 955 and 1500 mg TTP/
day/kg body weight, respectively, caused hepatic lipid
accumulation, while the 0.3 % TTP-diet (430 mg TTP/
day/kg body weight) did not (Fig. 3). The increase in
liver lipids was observed despite a lower feed intake and
weight gain in TTP-treated mice compared to control
mice. It is possible that the appetite was affected by the
TTP-diets; thus, the lack of a pair-fed control group is a
limitation of the study. Further investigations are
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Fig. 5 The effect of tetradecylthiopropionic acid (TTP) on plasma L-carnitine precursors, free L-carnitine, and L-carnitine esters. Male C57BL/6
mice were fed a low-fat control diet (black), or low-fat diets supplemented with 0.3 % (grey) (w/w), 0.6 % (dark grey) or 0.9 % (light grey) TTP for
2 weeks, and (a) L-carnitine, (b) γ-butyrobetaine, (c) palmitoylcarnitine, (d) octanoylcarnitine, (e) propionylcarnitine, (f) (iso)valerylcarnitine, and
(g) acetylcarnitine was measured in fasting plasma samples. Mean values with SD are presented (pooled samples from 2-3 mice, n = 3), and statistically
significant difference from control was determined by one-way ANOVA with Dunnett’s post hoc test (*P < 0.05, **P < 0.01, ***P < 0.001)
Table 4 Plasma fatty acid composition in control and TTP-treated micea
Diet groups
Fatty acid (wt %) Control 0.3 % TTP 0.6 % TTP 0.9 % TTP
Σ SFAs 32.1 ± 1.5 31.8 ± 0.9 31.2 ± 0.6 30.9 ± 0.6
Σ MUFAs 22.7 ± 2.2 20.6 ± 3.1 23.8 ± 4.8 22.2 ± 2.4
Σ n-6 PUFAs 36.9 ± 1.1 37.8 ± 2.1 35.0 ± 3.9 36.7 ± 2.1
C22:5n-6 0.29 ± 0.05 0.16 ± 0.04*** 0.14 ± 0.06*** 0.14 ± 0.04***
Σ n-3 PUFAs 7.8 ± 0.5 9.2 ± 0.8* 8.9 ± 1.7 8.7 ± 0.4
C20:5n-3 0.53 ± 0.07 0.62 ± 0.06 0.69 ± 0.22 0.70 ± 0.16
C22:5n-3 0.24 ± 0.03 0.31 ± 0.04 0.32 ± 0.11 0.33 ± 0.09
C22:6n-3 6.6 ± 0.5 7.7 ± 0.9 7.3 ± 1.4 7.2 ± 0.4
Σ n-3 PUFA/Σ n-6 PUFA ratiob 0.21 ± 0.02 0.24 ± 0.02* 0.25 ± 0.03** 0.24 ± 0.01*
Abbreviations: SFAs saturated fatty acids; MUFAs monounsaturated fatty acids; PUFAs polyunsaturated fatty acids; TTP tetradecylthiopropionic acid
aMeans with standard deviation are shown (n = 7–8), and results were analyzed by one-way ANOVA with Dunnett’s post hoc test (P* < 0.05,
P** < 0.01, P*** < 0.001)n-3
bPUFA/n-6 PUFA calculated
as: (18:4n-3 + 18:3n-3 + 20:3n-3 + 20:4n-3 + 21:5n-3 + 22:6n-3 + 22:5n-3)/(18:3n-6 + 18:2n-6 + 20:4n-6 + 20:3n-6 + 20:2n-6 + 22:5n-6 + 22:4n-6 + 22:2n-6)
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linked to the approximately 20 % lower feed intake in the
TTP-groups compared to control. For instance, a reduc-
tion in blood glucose was observed in TTP animals. As
hypoglycemic effects of drugs inhibiting β-oxidation have
previously been observed in rodents [20], the lower glu-
cose levels could also have been caused by a preference
for carbohydrate oxidation when β-oxidation is blocked.
In the present study we have shown that the plasma
concentrations of both free L-carnitine and γ-butyro-
betaine, a precursor of L-carnitine, were decreased in
TTP-treated mice (Fig. 5). This was associated with an in-
creased plasma level of the long-chain acylcarnitine palmi-
toylcarnitine, but no change in the gene expression of
acylcarnitine translocase (Fig. 5, Table 3). Thus, the TTP-
induced fatty liver resulted in increased consumption and/
or reduced biosynthesis of L-carnitine. In addition, the de-
creased mitochondrial fatty acid oxidation was associated
with decreased levels of short-chain acylcarnitines, espe-
cially acetylcarnitine. An accumulation of the long-chain
acylcarnitine palmitoylcarnitine is in line with an inhibited
CPT II activity [8–10]. Medium-chained fatty acids do not
depend on the carnitine shuttle for import to the mito-
chondria. Accordingly, the concentration of octanoylcarni-
tine was marginally affected in TTP-induced fatty liver.
In parallel with this, the hepatic gene expression of
Pparg and Ppargc1a were upregulated by TTP. PPARγ
may be implicated in liver steatosis development, as Pparg
expression was upregulated in high-fat diet induced liver
steatosis in mice, linked to a reduced expression of the
PPARγ inhibitor cAMP response element-binding protein
(Creb) [21, 22]. However, in some studies, PPARγ agonists
were able to ameliorate NAFLD, probably through in-
creased β-oxidation [23]. In the current study, increased
activities of CPT I and II and ACOX1 were observed. The
data suggest that the increased activities of mitochondrial
and peroxisomal enzymes probably serve as a compensa-
tory mechanism to TTP-inhibition of mitochondrial β-
oxidation. Indeed, in the case of L-carnitine deficiency, a
compensatory increase in CPT I was observed [24]. Dys-
regulated lipogenesis and TAG biosynthesis were probably
not involved in TTP-induced steatosis-development as
there was no difference between groups in gene expres-
sion of ATP citrate lyase (Table 3) or the activities of FAS
and GPAT. Production of VLDL did not seem to be influ-
enced, as ApoB gene expression remained constant. Thus,
hepatic steatosis was probably induced when the amount












































































































































Fig. 6 The effect of tetradecylthiopropionic acid (TTP) on antioxidative and anti-inflammatory parameters. Male C57BL/6 mice were fed a low-fat
control diet (black), or low-fat diets supplemented with 0.3 % (grey) (w/w), 0.6 % (dark grey) or 0.9 % (light grey) TTP for 2 weeks. Levels of (a)
plasma total antioxidant capacity, (b) plasma anti-inflammatory fatty acid index, (c) liver anti-inflammatory fatty acid index, (d) plasma double
bond index (DBI), (e) liver DBI were as indicated. Mean values with SD are presented (a: n = 3–8; b–e: n = 7–8), and statistically significant
difference from control was determined by one-way ANOVA with Dunnett’s post hoc test (*P < 0.05)
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TTP treatment induced changes in liver and plasma
fatty acid composition, including an increased n-3 to n-6
PUFA ratio in both liver and plasma. We have previously
reported that EPA, but not DHA, is efficiently metabo-
lized through mitochondrial oxidation of fatty acids.
DHA is, however, a good substrate for the peroxisomal
fatty acid oxidation system, which is also active in chain
shortening of fatty acids [25]. Accordingly, in a situation
with impaired mitochondrial fatty acid oxidation cap-
acity, but increased peroxisomal β-oxidation, the hepatic
EPA may increase whereas DHA may decrease. Indeed,
the hepatic level of DHA decreased after TTP treatment
whereas the hepatic content of DPA, an intermediate
fatty acid between EPA and DHA, increased. The hep-
atic level of EPA remained constant whereas the plasma
concentration of both EPA and DPA increased in mice
treated with TTP (Table 4). It has been reported that
dietary EPA supplementation accentuates hepatic TAG
accumulation in mice with impaired fatty acid oxidation
capacity [26]. It was also of interest that the relative
amount of long-chain SFAs, MUFAs and n-6 fatty acids
decreased after TTP treatment, while the content of
C12:0 and C14:0 was increased. Accordingly, impaired
mitochondrial fatty acid oxidation may lead to an accu-
mulation of medium-chain SFAs and MUFAs ≤C18 in
liver. Whether this is due to increased peroxisomal fatty
acid chain shortening or increased oxidative stress [17],
should be considered. Most probably this is due to in-
creased fatty acid shortening by peroxisomes as the
plasma antioxidant capacity and the hepatic gene ex-
pression of SOD1 increased (Table 3). This was unex-
pected as SOD1 is involved in the prevention of TAG
accumulation during high-fat diet induced steatosis in
mice [27]. Due to the presence of a sulfur atom in the car-
bon backbone, TTP potentially has antioxidant capacity,
as shown for carbon-3 thia-fatty acids [28]. In further
studies it will be interesting to investigate mitochondrial
markers of oxidative stress, as well as the effect of TTP on
oxidative phosphorylation. The almost 50 % reduction of
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Fig. 7 The effect of tetradecylthiopropionic acid (TTP) on plasma one-carbon metabolites in mice. Male C57BL/6 mice were fed a low-fat control
diet (black), or low-fat diets supplemented with 0.3 % (grey) (w/w), 0.6 % (dark grey) or 0.9 % (light grey) TTP for 2 weeks, and (a) sarcosine, (b)
betaine, (c) dimethylglycine (DMG), (d) glycine, (e) serine, (f) methionine (Met), (g) Met-sulfoxide, (h) total homocysteine (tHcy), (i) cystathionine,
(j) total cysteine, and (k) trimethyllysine was measured in fasting plasma samples. Mean values with SD are presented (pooled samples from 2–3
mice, n = 3), and statistically significant difference from control was determined by one-way ANOVA with Dunnett’s post hoc test (*P < 0.05,
**P < 0.01). l There was a positive association between hepatic TAG and plasma tHcy as demonstrated by linear regression
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index (Fig. 6) further suggested that no increased inflam-
mation followed 2 weeks TTP administration. Accordingly
the hepatic gene expression of IL-1β and TNFα decreased
(Table 3). A prolonged treatment period might have re-
sulted in monocyte recruitment and increased inflamma-
tion associated with steatohepatitis [29].
Fatty liver and plasma total homocysteine
One-carbon metabolism is closely linked to lipid homeosta-
sis, primarily through the role of methyl-groups in the for-
mation of phosphatidylcholine by the phosphatidyl-
ethanolamine methyltransferase (PEMT) pathway [30–33].
Methyl donor supplementation has been shown to alleviate
NAFLD and reduce plasma acylcarnitines in mice [34]. The
plasma Hcy level is linked to regulation of PPARs, suggest-
ing that hyperhomocysteinemia is associated with alteration
of intracellular lipid metabolism [35]. We observed a sub-
stantial increase in plasma tHcy in TTP treated animals de-
veloping fatty liver, which is in line with elevated plasma
tHcy levels previously observed in NAFLD patients [36]. In
the present study of TTP-induced fatty liver a strong cor-
relation was observed between hepatic TAG concentration
and plasma tHcy (Fig. 7l). These data support the view that
increased levels of tHcy may be associated with hepatic
steatosis at least in this model. The tHcy increase may be a
consequence of reduced activity in all three pathways of
Hcy metabolism as the gene expression of the rate-limiting
enzyme in each pathway was significantly reduced. De-
creased plasma methionine and methionine sulfoxide sup-
ports that TTP induced fatty liver is associated with a
reduced hepatic methylation potential, and elevated plasma
betaine specifically indicate that BHMT remethylation was
low. There is currently no available biomarker for the
evaluation of the remethylation associated with the folate
cycle. Moreover, there were no associations between plasma
levels of coenzymes, markers of B-vitamins and one-carbon
metabolites (data not shown). TTP has a small PPARα acti-
vation effect [37] and PPARα activation by WY-14,643 has
previously shown to increase the production of nicotina-
mide [38]. Thus, higher plasma nicotinamide observed in
TTP-treated animals may be due to PPARα-induced syn-
thesis. Notably, fibrate treatment was previously shown to
increase plasma tHcy [39, 40], supporting a possible role of
PPARα in the hyperhomocysteinemia in response to TTP
treatment.
Fatty liver and metabolites of the choline oxidation
pathway
In line with a possible reduced methylation potential in
TTP-treated animals, plasma L-carnitine, requiring 3
methylation steps to be produced, was significantly re-
duced. However, the plasma concentration of 6-N-
trimethyllysine, a methylated amino acid and L-carnitine
precursor, did not decrease in TTP-induced fatty liver.
Glycine, generated during L-carnitine biosynthesis, was
not altered in plasma. Glycine can also be produced from
serine in the cell cytosol and mitochondria via SHMT1
and SHMT2, respectively (Fig. 1), and the gene expression
of mitochondrial SHMT2 was downregulated. Sarcosine,
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Fig. 8 The effect of tetradecylthiopropionic acid (TTP) on plasma B-vitamins and derivatives. Male C57BL/6 mice were fed a low-fat control diet
(black), or low-fat diets supplemented with 0.3 % (grey) (w/w), 0.6 % (dark grey) or 0.9 % (light grey) TTP for 2 weeks, and (a) flavin mononucleotide,
(b) riboflavin, (c) nicotinamide, (d) pyridoxal 5′-phosphate, (e) pyridoxal, (f) 4-pyridoxic acid, and (g) methylmalonic acid (MMA), was measured in fasting
plasma samples. Mean values with SD are presented (pooled samples from 2-3 mice, n = 3), and statistically significant difference from control was
determined by one-way ANOVA with Dunnett’s post hoc test (*P < 0.05)
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produced from glycine in the cell cytosol via GNMT.
The gene expression of GNMT was, however, un-
changed. Finally, glycine can be produced from sarco-
sine by the mitochondrial B2-dependent SARDH
enzyme, which was downregulated, suggesting that re-
duced sarcosine catabolism may have contributed to the
higher plasma concentration of sarcosine during TTP-
induced fatty liver. Moreover, the concentration of the
mitochondrial metabolite DMG was increased after
TTP administration, despite a reduction in the gene ex-
pression of Bhmt. The increased concentration of DMG
in TTP-induced fatty liver could be explained by de-
creased catabolism of DMG, in line with the observed
reduction in Dmgdh gene expression.
Conclusions
Our results suggest that the hepatic steatosis induced by
the modified fatty acid analogue TTP is most likely due to
inhibited mitochondrial fatty acid oxidation capacity, and
is associated with accumulation of long-chain L-carnitine
derivatives and altered hepatic fatty acid composition. We
demonstrate that TTP-induced mitochondrial dysfunction
and hepatic steatosis can influence tHcy levels and one-
carbon metabolites without an increase in oxidative stress.
Because TTP affected B-vitamin status and gene expres-
sion of enzymes involved in choline oxidation and Hcy
metabolism, the influence of one-carbon and Hcy metab-




Male C57BL/6 mice (Taconic, Denmark), 12 weeks old,
were housed in Makrolon III cages, 2-3 animals per
cage, in an open system. They were kept under standard
laboratory conditions with temperature 22 ± 1 °C, dark/
light cycles of 12/12 h, relative humidity 55 ± 5 % and 20
air changes per hour. The animal study was conducted
according to the Guidelines for the Care and Use of
Experimental Animals, and the Norwegian State Board
of Biological Experiments with Living Animals approved
the protocol (FOTS ID: 2013/5077).
Animals were divided at random into 4 groups of 8
mice, and after 7 days of acclimatization, control groups
were fed a diet with 7 % (w/w) fat (5 % lard and 2 % soy
oil, Dyet Inc., Bethlehem, PA, USA) while the interven-
tion diets were supplemented with 0.3 %, 0.6 % or 0.9 %
TTP. TTP was manufactured as previously described
[41]. Isoenergetic diets were made as described in
Table 5, containing 19 % (w/w) protein from casein,
cornstarch, dyetrose, sucrose, fiber, AIN-93-MX mineral
mix, AIN-93-VX vitamin mix, L-cysteine, choline bitar-
trate (Dyet Inc.) and tert-Butyl-hydroquinone (Sigma Al-
drich, St. Louis, MO, USA). All groups had free access
to tap water and feed during the 14 days experiment.
Mice feed intake and weight gain were determined twice
a week. All mice were killed on day 14. They were anes-
thetized by inhalation of 2 % isofluorane (Forane, Abbot
Laboratories Ltd, Illinois, USA) in an anesthesia cham-
ber and thoracotomy, cardiac puncture, and exsanguin-
ation was performed. Plasma and snap-frozen liver
samples were stored at -80 °C.
Hepatic enzyme activities
At sacrifice, livers were removed, and weighed. One part
of the liver was immediately snap-frozen in liquid nitro-
gen, while 100 mg liver from each mouse was chilled on
ice and homogenized in 1 mL ice-cold sucrose medium
(0.25 M sucrose, 10 mM HEPES, and 1 mM Na4EDTA,
adjusted to a pH of 7.4 with KOH) giving 10 % (w/v).
The homogenates were centrifuged at 600 g-force for
10 min at 4 °C and the post-nuclear fraction was re-
moved and used for further analysis. The mitochondrial
fatty acid oxidation in the absence and presence of
malonyl-CoA was assayed as previously described [42].
The assay for CPT I and II was performed on frozen
homogenate according to Bremer et al. [43], but with
some modifications [44]. The activity of ACOX1 was
measured in the post-nuclear fraction, as described by
Madsen et al. [25]. FAS and GPAT activities were mea-
sured in the post-nuclear fraction as described by Skorve
et al. [45] with some modifications [44]. ACSL activity
was measured according to Bar-Tana, Rose and Shapiro
[46]. HMG-CoA synthase was measured as described by
Clinkenbeard et al. [47]. Citrate synthase was deter-
mined according to Stadlmann et al. [48].
Table 5 Composition of the experimental dieta








AIN-93G-MX mineral mix 3.4




aValues shown are g component per 100 g diet. The energy contribution from
protein, fat, and carbohydrates was 19.5, 16, and 64.5 %, respectively, and
100 g diet contained 381.4 kcal. TTP was added to the complete diet at a dose
of 0.3, 0.6 or 0.9 g per 100 g
bThe casein contained 86.5 % protein
Berge et al. Lipids in Health and Disease  (2016) 15:24 Page 13 of 16
Histology
Cryo-sections from frozen livers were generated using a
1720 Cryostat (Leica Microsystems, Wetzlar, Germany)
from 3 mice per group. Sections were fixed in 4 %
buffered formalin for 10 min, rinsed 3× in dH2O, be-
fore staining in 0.7 % (w/v) Oil Red O (Sigma) in
propylene glycol for 10 min, rinsed 3× dH2O, and
stained with hematoxylin (Thermo Fisher Scientific,
Waltham, MA, USA) for 2 min. Finally, sections were
rinsed 3× dH2O and mounted with ImmuMount
(Thermo Fisher Scientific). Images were captured
using an Olympus BX51 light microscope at 40×
magnification with an Olympus DP25 digital colour
camera (Olympus Corporation, Tokyo, Japan). Three
images were captured from each animal by a blinded
investigator.
Biochemical analyses
Liver lipids were extracted according to Bligh and Dyer
[49], evaporated under nitrogen, and redissolved in isopro-
panol before analysis. Lipids from liver extracts or plasma
were then measured enzymatically on a Hitachi 917 system
(Roche Diagnostics GmbH, Mannheim, Germany) using
the TAG (GPO-PAP) and cholesterol kit (CHOD-PAP)
from Roche Diagnostics, and the free fatty acid kit and
phospholipid kit from Diasys Diagnostic systems GmbH
(Holzheim, Germany). A kit from Roche was used to deter-
mine the plasma activities of ALT. Total liver fatty acid
composition was analyzed in liver extracts and plasma
using GC/MS as previously described [50]. The DBI was
calculated according to the formula: (total MUFA +
2*(C18:2n-6 + C20:2n-6 + C22:2n-6) + 3*(C18:3n-6 + C18:
3n-3 + C20:3n-9 + C20:3n-6) + 4*(C18:4n-3 + C20:4n-6 +
C22:4n-6) + 5*(C20:5n-3 +C21:5n-3 +C22:5n-6 +C22:5n-3)
+ 6*C22:6n-3)/total fatty acids. The anti-inflammatory
fatty acid index was calculated according to the for-
mula: ((20:5n-3 + 20.3n-6 + 22:6n-3/20:4n-6)) × 100.
Free carnitine, acetyl-, octanoyl-, palmitoyl-, propionyl-,
and (iso)valerylcarnitines, and the precursors for carnitine,
butyrobetaine and trimethyl lysine, were analyzed in plasma
using LC MS/MS as previously described [51] with some
modifications [52]. Plasma methylmalonic acid, tHcy, sarco-
sine, serine and glycine were analyzed by GC-MS/MS [53].
Plasma choline, betaine, DMG, methionine, methionine
sulfoxide, cysteine, [54], all vitamin B2, B3, and B6 forms
[flavine mononucleotide, riboflavin, nicotinamide, N1-
methylnicotinamide, pyridoxal 5′ phosphate, pyridoxal, 4-
pyridoxic acid], and cystathionine [55] were analyzed by
LC-MS/MS at Bevital A/S (http://www.bevital.no; Bergen,
Norway) according to Midttun, Hustad and Ueland [55].
Total antioxidant capacity of plasma was measured using
the total antioxidant capacity kit (Abcam, Cambridge, UK)
according to the manufacturer’s instructions.
Gene expression analysis
Total cellular RNA was purified from frozen liver samples,
and cDNA was produced as previously described [56].
Real-time PCR was performed with Sarstedt 384 well
multiply-PCR Plates (Sarstedt Inc., Newton, NC, USA) on
the following genes, using probes and primers from Ap-
plied Biosystems: Chka (Mm00442759_m1), Chkb (Mm
04213225_s1), Chdh (Mm00549261_m1), Bhmt (Mm04
210521_g1), Dmgdh (Mm00512022_m1), Sardh (Mm0045
4657_m1), Shmt1 (Mm00486110_m1), Shmt2 (Mm00659
512_g1), Gnmt (Mm00494688_m1), Mtr (Mm01340
053_m1), Mtrr_(Mm00549978_m1), Msra (Mm00452
738_m1), Msrb2 (Mm00512937_m1), Cbs (Mm00460
654_m1), Cth (Mm00461247_m1), Ppargc1a (Mm004
47183), Pparg (Mm00440945), Ppara (Mm00440939),
CD36/Fat (Mm00432403), Fabp1 (Mm00444340), Lipe
(Mm00495359), Acly (Mm01302282_m1), Slc25a20 (Mm
00451571_m1), Lipc (Mm00433975), Apob (Mm0154
5156_m1), IL1β (Mm01336189_m1), Sod1 (Mm01344
233_m1), Sod2 (Mm01313000_m1), Tnfα (Mm00443
258_m1) and Pcyt1a (Mm00447774_m1).
Three different reference genes were included: 18 s
[Kit-FAM-TAMRA (Reference RT-CKFT-18 s)] from
Eurogentec, Belgium, glyceraldehyde-3-phosphate de-
hydrogenase (Gapdh, Mm99999915_g1) from Applied
Biosystems, and ribosomal protein, large, P0 (Rplp0,
Gene ID 11837) from Thermo Fisher Scientific. The
NormFinder software was used to evaluate the reference
genes [57], and data normalized to 18 s are presented.
Statistical analysis
Data was analyzed using Prism Software (Graph-Pad Soft-
ware, San Diego, CA) to determine statistical significance.
The results are shown as means of 7-8 animals per group
with their standard deviations. Plasma samples were
pooled to obtain enough material, and three samples per
group were analyzed, as indicated in figure legends. Nor-
mal distribution was determined by the Kolmogorov-
Smirnov test (with Dallal-Wilkinson-Lilliefor P value),
when possible. One-way ANOVA with Dunnett’s post
hoc test was performed to evaluate statistical differences
between groups. Unpaired t-test was used to analyze
gene expression results, and to determine tendencies. P-
values < 0.05 were considered statistically significant.
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